Answers are grounded in this paper and cite their sources.
Purpose: The presence of Hyaluronidase (HAase) in the human body has garnered significant attention among urologists and researchers due to its crucial role and the accurate measurement methods in early detection of bladder carcinoma, which is classified as the fourth most predominant malignancy among the 5 leading oncological afflictions in the male population and seventh in all gender population over the past quinquennium. The use of a cutoff value of 10 mU/mg has proven to offer a good balance in its diagnostic value. By integrating meta-analysis data and the latest research, HAase-based approaches could become a revolutionary step toward enhancing diagnostic accuracy while reducing dependence on invasive procedures. Materials and methods: PICO strategy and PRISMA guideline were utilized to evaluate the diagnostic value of urinary HAase as a noninvasive modality for the detection of bladder carcinoma specifically focused on diagnostic test accuracy studies. Key metrics were defined as follows: sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, positive predictive value, negative predictive value, diagnostic odds ratio, and the area under the curve (AUC). Statistical analyses were performed using Meta-DiSc version 1.4 and R Studio version 4.2.2. The sensitivity analysis was conducted in the form of subanalyses where the comparisons will be conducted by stratifying the studies based on the urinary HAase concentration 10 mU/mg cutoff. Results: A total of 2786 voided urine samples were analyzed across 15 studies, the pooled of both Sn, Sp, LR+, LR−, DOR, PPV, and NPV in all concentration was estimated at 0.87 (95% CI: 0.85-0.90, I ² = 66.4%); 0.88 (95% CI: 0.84-0.92, I ² = 88.4%); 6.93 (95% CI: 4.84-9.91, I ² = 79.9%); 0.16 (95% CI: 0.12-0.20, I ² = 61.8%); 54.11 (95% CI: 30.15-97.11, I ² = 76.7%); 0.90 (95% CI: 0.83-0.95, I ² = 84.9%); 0.86 (95% CI: 0.81-0.90, I ² = 77.6%), respectively. In a cutoff concentrations of ≤10 mU/mg urine HAase, the pooled of both same diagnostic outcome was 0.85 (95% CI: 0.81-0.89, I ² = 75.1%); 0.82 (95% CI: 0.80-0.85, I ² = 0%); 4.67 (95% CI: 4.01-5.44, I ² = 7.6%); 0.20 (95% CI: 0.15-0.26, I ² = 47.3%); 24.52 (95% CI: 16.67-36.05, I ² = 38.4%); 0.81 (95% CI: 0.73-0.87; I ² = 77.9%); 0.85 (95% CI: 0.77-0.91; I ² = 77.3%). In the subgroup with a urinary HAase cutoff concentration >10 mU/mg the pooled of both diagnostic outcome was 0.92 (95% CI: 0.89-0.94, I ²=43.1%); 0.97 (95% CI: 0.92-0.98, I ² = 81.7%); 29.29 (95% CI: 10.20-84.09, I ² = 70.8%); 0.09 (95% CI: 0.07-0.13, I ²=20.8%); 381.23 (95% CI: 162.35-895.24, I ²= 22.6%); 0.97 (95% CI: 0.93-0.99; I ² = 71.6%); 0.87 (95% CI: 0.80-0.92; I ² = 80.6%). Conclusion: The superior diagnostic precision of urinary HAase in identifying bladder cancer has been rigorously established in this meta-analysis, specifically if we take a concern in >10 mU/mg cutoff concentration. Urinary HAase testing offers a pivotal prescreening noninvasive method, and its easily accessible nature underscores its clinical appeal, presenting a compelling case for its integration into early detection protocols.
No takes yet. Share an insight, caveat, or question.
Ikram et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: